SG Americas Securities LLC Acquires 6,727 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

SG Americas Securities LLC raised its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 23.2% in the fourth quarter, Holdings Channel reports. The firm owned 35,774 shares of the company’s stock after acquiring an additional 6,727 shares during the quarter. SG Americas Securities LLC’s holdings in Organogenesis were worth $146,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ORGO. Baird Financial Group Inc. bought a new stake in Organogenesis during the 4th quarter valued at about $29,000. Point72 Hong Kong Ltd increased its stake in Organogenesis by 245.7% during the 2nd quarter. Point72 Hong Kong Ltd now owns 6,015 shares of the company’s stock valued at $29,000 after purchasing an additional 4,275 shares in the last quarter. Principal Financial Group Inc. bought a new stake in Organogenesis during the 3rd quarter valued at about $32,000. Jane Street Group LLC bought a new stake in Organogenesis during the 4th quarter valued at about $37,000. Finally, Ameritas Investment Partners Inc. increased its stake in Organogenesis by 80.1% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock valued at $41,000 after purchasing an additional 2,396 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $5.00 price target on shares of Organogenesis in a research report on Friday, March 1st. BTIG Research upped their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Wednesday, December 27th.

Organogenesis Trading Up 3.6 %

Shares of ORGO opened at $2.86 on Wednesday. Organogenesis Holdings Inc. has a twelve month low of $1.79 and a twelve month high of $4.70. The company has a market cap of $377.41 million, a P/E ratio of 71.52 and a beta of 1.57. The company has a current ratio of 2.80, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. The company’s fifty day simple moving average is $3.08 and its 200-day simple moving average is $3.09.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.